|
|
|
| Effect of Rosuvastatin Combined with Tegrarol in the treatment of Acute Coronary Syndrome and its Effect on YKL-40 and GMP-140 |
| TANG Ningcheng, YANG Wei, WU Haiyi |
| Rugao People's Hospital, Jiangsu Rugao 226500, China |
|
|
|
|
Abstract Objective: To study curative efficacy of risuvastatin in combination with tigreglio in treatment of Acute coronary syndromeand its effectson Plasma chitinase protein 40 (ykl-40), plasma alpha - granular membrane protein (gmp-140). Methods: 100 patients with acute coronary syndrome admitted to our hospital from April 2016 to April 2018 were selected for this study, the patients were divided into observation group (n=52) and control group (n=48) by simple random grouping. The control group was treated with tigrelol, and the observation group was treated with risuvastatin on the basis of the control group. The clinical efficacy, serum ykl-40, gmp-140, BNP, LVEF and adverse reactions were compared between the two groups. Results: After treatment, the total effective rates of the two groups were 90.38% and 72.92%, respectively (P<0.05). After treatment, the levels of ykl-40 and gmp-140 in both groups were significantly improved, and the observation group was significantly lower than the control group (P<0.05). Before treatment, there was no significant difference in BNP and LVEF levels between the two groups. After treatment, BNP and LVEF in both groups were significantly improved compared with that before treatment, and BNP level in the observation group was significantly lower than that in the control group, while LVEF was significantly higher than that in the control group (P<0.05). The incidence of adverse reactions in the two groups was 7.69% and 29.17% respectively (P<0.05). Conclusion: The use of rosuvastatin combined with tigrelol in acute coronary syndrome has significant curative effect and can effectively improve the levels of ykl-40 and gmp-140, which is worthy of promotion and application.
|
|
|
|
|
|
[1] 郑鳕洋,厉娜,黄志刚,等.替格瑞洛对急性冠状动脉综合征患者急诊经皮冠状动脉介入术后造影剂肾病的影响[J].疑难病杂志,2017,16(1):1~5.
[2] Davlouros P, Xanthopoulou I, Goudevenos J, et al. Contemporary antiplatelet treatment in acute coronary syndrome patients with impaired renal function undergoing percutaneous coronary intervention.[J]. Cardiology, 2017, 138(3):186~194.
[3] 孙秀全,杜丽霞,杨立斌.瑞舒伐他汀强化治疗对急性冠状脉综合征患者介入术后低密度脂蛋白胆固醇与高敏C反应蛋白水平的影响[J].陕西医学杂志,2017,46(9):1277~1279.
[4] 林伟,周瑞,林建锋,等.替格瑞洛对急性冠脉综合征氯吡格雷用药低反应性患者的临床疗效观察[J].中华全科医学,2017,15(6):934~936.
[5] 张俊峰,曹爱芝,李征.瑞舒伐他汀对行经皮冠状动脉介入治疗的急性冠状动脉综合征患者术后炎症反应及冠脉再狭窄的影响[J].实用临床医药杂志,2017,21(13):154~156.
[6] 毛建斌.瑞舒伐他汀联合替格瑞洛对行经皮冠状动脉介入治疗的冠心病患者的影响[J].实用心脑肺血管病杂志,2017,25(11):93~95.
[7] Bergmark B A, Cannon C P, White W B, et al. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial[J]. Diabetes Obesity & Metabolism, 2017, 19(7):962~969. |
| [1] |
. [J]. HeBei Med, 2019, 25(6): 919-921. |
|
|
|
|
2019, Vol. 25 
